Becton's $200 Mil. Clontech Buy Broadens Life Science Research Offerings
This article was originally published in The Gray Sheet
Executive Summary
Becton Dickinson's $200 mil. acquisition of molecular biology research products maker Clontech Labs will significantly broaden the BD Biosciences life science research product line, according to the company.
You may also be interested in...
BD’s R&D Pipeline Includes Micro-Needle Drug Delivery; Q4 Sales Up 8%
BD is preparing for functionality testing of its development-stage Micro Infuser wearable drug-delivery system, incorporating micro-needles to deliver drugs just below the skin's surface to minimize pain
BD’s R&D Pipeline Includes Micro-Needle Drug Delivery; Q4 Sales Up 8%
BD is preparing for functionality testing of its development-stage Micro Infuser wearable drug-delivery system, incorporating micro-needles to deliver drugs just below the skin's surface to minimize pain
Becton Dickinson/Clontech Laboratories
BD expects to complete its acquisition of molecular biology research products maker Clontech by Aug. 31. Under a revision of their April 28 merger agreement (1"The Gray Sheet" May 3, p. 13), the deal will now be for $200 mil. in cash instead of stock